Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase III, Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy

To evaluate the effectiveness and safety of obinutuzumab compared to tacrolimus in patients with primary membranous nephropathy

Agree to participate in one of two treatment groups, attend scheduled study visits and have blood drawn for samples. will have visits approximately every 2 to 14 weeks during the first two years of the study, every 12-16 weeks in the third and fourth years of the study, and then every 26 weeks until you finish the study. Visits will usually last 1-3 hours, but visits that require an obinutuzumab infusion may last 6 hours. Your total time in the study will be a minimum of about 4 years, but could be up to about 9 years, depending on how the treatment affects your disease.

$100.00 per visit

Umar Farooq
Kim Hitz - at or 717-531-4924

18 year(s) or older
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of primary membranous nephropathy
age 18-75
ability to comply with requried study procedures
stable blood pressure

Exclusion Criteria:
secondary cause of membranous nephropathy
uncontrolled blood pressure
kidney transplant or dialysis
Type 1 or type 2 diabetes
Kidney & Urinary System
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,